3
Announcements
Trials
Browse
Landscape
Phase
Phase 3
1
Status
Terminated
1
Sponsor Class
INDUSTRY
1
Study Type
Interventional
1
Sponsor
Cancer Type
CNS
1
Conditions
Neoplasms
10
Colorectal Cancer Metastatic
6
Neoplasm Metastasis
5
Lymphoma, Non-Hodgkin
5
Colorectal Neoplasms
5
Precursor Cell Lymphoblastic Leukemia-Lymphoma
4
Lymphoma, Mantle-Cell
4
Lymphoma, Large-Cell, Immunoblastic
4
Lymphoma, Large B-Cell, Diffuse
4
Lymphoma, Follicular
4
Lymphoma, B-Cell, Marginal Zone
4
Leukemia, Lymphocytic, Chronic, B-Cell
4
Burkitt Lymphoma
4
Uterine Cervical Neoplasms
3
Prostatic Neoplasms
3
Ovarian Neoplasms
3
Lung Neoplasms
3
Carcinoma, Non-Small-Cell Lung
3
Vulvar Neoplasms
2
Vaginal Neoplasms
2
Urinary Bladder Neoplasms
2
Urethral Neoplasms
2
Testicular Neoplasms
2
Sarcoma
2
Penile Neoplasms
2
Lymphoma
2
Fallopian Tube Neoplasms
2
Endometrial Neoplasms
2
Carcinoma, Ovarian Epithelial
2
Carcinoma, Hepatocellular
2
Interventions
emvododstat
1
brolucizumab
1
aflibercept
1
HDAC-42
1
Date Range
30 days
90 days
1 year
All
Options
Has results
Has announcements
Clinical Trials
1 trials
Recent
Start date
Enrollment
INDUSTRY
×
Neurofibromatosis 2
×
aflibercept
×
Clear all
NCT03710564
2023-01-30
MERLIN
Novartis
Phase 3
Terminated
535 enrolled
14 charts